GlassScriptPhysician profile
Joanna Y Du
NPI 1477731677
$3,276.08
in general payments reported to CMS, 2019-2025
36 companies · $195 in 2025
The $195 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $586 · 2020: $185 · 2021: $355 · 2022: $743 · 2023: $690 · 2024: $522 · 2025: $195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,407.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,407.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $812.47 | 2020-2023 | Orilissa, Lo Loestrin Fe, Liletta |
| Astellas Pharma US INC | $235.69 | 2023-2025 | Veozah |
| Pfizer INC. | $165.61 | 2022-2024 | |
| Aspira Women'S Health INC | $159.87 | 2020-2024 | Ova1 |
| Abbott Laboratories | $156.24 | 2024 | Freestyle Libre 3 |
| Duchesnay USA Incorporated | $151.29 | 2019 | |
| Myovant Sciences INC. | $149.70 | 2021-2022 | |
| Therapeuticsmd, INC. | $119.85 | 2019-2021 | |
| Amgen INC. | $118.18 | 2019 | |
| Revance Therapeutics, INC. | $117.50 | 2024 | Daxxify |
| E.R. Squibb & Sons, L.L.C. | $111.36 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $105.30 | 2021-2024 | |
| Phadia US INC. | $90.10 | 2022 | |
| Merck Sharp & Dohme LLC | $85.97 | 2019-2022 | |
| Minerva Surgical, INC | $76.08 | 2019-2024 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $74.37 | 2021-2025 | |
| Exeltis, USA INC. | $65.86 | 2019-2025 | Slynd |
| Shield Therapeutics INC | $52.86 | 2023 | Accrufer |
| Pacira Pharmaceuticals Incorporated | $41.41 | 2021-2022 | |
| Amag Pharmaceuticals, INC. | $39.32 | 2019-2020 | |
| Boston Scientific Corporation | $33.64 | 2025 | Bulkamid |
| Mimedx Group, INC. | $29.80 | 2024 | |
| Meditrina | $28.20 | 2024-2025 | |
| Smith+Nephew, INC. | $27.84 | 2025 | Stravix |
| Channel Medsystems, INC. | $25.27 | 2022-2023 | |
| Evofem Biosciences, INC. | $24.52 | 2022-2025 | Solosec, Phexx, Phexxi |
| Biohaven Pharmaceuticals, INC. | $23.59 | 2021 | |
| Allergan, INC. | $21.37 | 2019 | |
| Roche Diagnostics Corporation | $20.94 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.94 | 2022 | |
| Sumitomo Pharma America, INC. | $18.69 | 2024 | Myfembree |
| Vertex Pharmaceuticals Incorporated | $16.63 | 2025 | |
| Avion Pharmaceuticals | $14.67 | 2021 | |
| Coopersurgical, INC. | $14.47 | 2022 | |
| Hologic Sales and Service, LLC | $14.27 | 2025 | Thinprep 2000 Processor |
| Dysis Medical, INC. | $13.21 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joanna Du listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.